Parkinson's Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort

J Parkinsons Dis. 2020;10(2):707-709. doi: 10.3233/JPD-191782.

Affiliations

¹ University College London, Institute of Neurology, Department of Neuromuscular Disorders, Queen Square, London, UK.
² South Kazakhstan Medical Academy, Department of Neurology, Shymkent, Kazakhstan.
³ Semey Medical University, Department of Neurology, Semey, Kazakhstan.
⁴ Institute of Neurology Named After S.K. Kaishibayev, Almaty, Kazakhstan.
⁵ Astana Medical University, Nur-Sultan, Kazakhstan.

No abstract available

Keywords: Central Asia; Parkinson’s disease; Parkinson’s disease in Asia; age of onset; progression.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Age of Onset
Aged
Aged, 80 and over
Antiparkinson Agents / administration & dosage*
Disease Progression
Female
Humans
Kazakhstan / epidemiology
Levodopa / administration & dosage*
Male
Middle Aged
Parkinson Disease / classification
Parkinson Disease / drug therapy*
Parkinson Disease / epidemiology*
Parkinson Disease / physiopathology
Retrospective Studies
Sex Factors
Young Adult

Substances

Antiparkinson Agents
Levodopa

Grants and funding